Search

everythinglearnresearchcommunity

for

Search:↓

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

Core symptoms in breast cancer chemotherapy remain stable, aiding targeted interventions.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.

High-dose intravenous iron therapy doesn't interfere with treatment improvements in IBD patients with iron deficiency anemia.

The new delivery method for dutasteride is more effective and has fewer side effects.

BOOST is a promising, easy-to-use treatment for diabetic foot ulcers that improves healing by reducing inflammation and promoting blood vessel growth.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.

Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.

Oral valganciclovir improved a patient's skin condition caused by immunosuppression.

Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.

PLD is an effective and safer alternative for treating breast cancer.

Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

Compound 6 is a promising candidate for better wound healing.

Topical 5-Fluorouracil can rarely cause nerve damage, especially in people with a certain genetic deficiency.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.